109274-83-1

Basic information

• Product Name: ETHYL 3-HYDROXYFURO[2,3-B]PYRIDINE-2-CARBOXYLATE
• Synonyms: ETHYL 3-HYDROXYFURO[2,3-B]PYRIDINE-2-CARBOXYLATE;3-Hydroxy-furo[2,3-b]pyridine-2-carboxylic acid ethyl ester;Ethyl 3-hydroxyfuro[2,3-b]pyridine-2-carboxylate hydrochloride
• CAS NO: 109274-83-1
• Molecular Formula: C10H9NO4
• Molecular Weight: 207.18276
• Mol File: 109274-83-1.mol

Chemical Properties

• Boiling Point: 311.699 °C at 760 mmHg
• Flash Point: 142.31 °C
• Appearance: /
• Density: 1.359 g/cm³
• PKA: 6.07±0.50(Predicted)
• CAS DataBase Reference: ETHYL 3-HYDROXYFURO[2,3-B]PYRIDINE-2-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 3-HYDROXYFURO[2,3-B]PYRIDINE-2-CARBOXYLATE(109274-83-1)
• EPA Substance Registry System: ETHYL 3-HYDROXYFURO[2,3-B]PYRIDINE-2-CARBOXYLATE(109274-83-1)

Safety Data

• Hazardous Substances Data: 109274-83-1(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
ETHYL 3-HYDROXYFURO[2,3-B]PYRIDINE-2-CARBOXYLATE is used as a building block for the synthesis of various bioactive compounds due to its furo[2,3-b]pyridine core structure, which is important in drug discovery and development.
Used in Drug Discovery and Development:
ETHYL 3-HYDROXYFURO[2,3-B]PYRIDINE-2-CARBOXYLATE is used as a versatile intermediate in organic synthesis for the development of new pharmaceuticals with potential antiviral, antibacterial, and antifungal properties.

Upstream product

• 623-50-7 ethyl 2-hydroxyacetate 
• 1452-94-4 ethyl 2-chloronicotinate 
• 2942-59-8 2-chloronicotinic acid 

Downstream Products

• 27038-48-8 furo<2,3-b>pyridin-3(2H)-one 
• 109275-03-8 2-(3-furo<2,3-b>pyridyl)furo<2,3-b>pyridin-3-ol 
• 109274-90-0 3-Methyl-furo[2,3-b]pyridine 

Relevant articles and documents

Hinge Binder Scaffold Hopping Identifies Potent Calcium/Calmodulin-Dependent Protein Kinase Kinase 2 (CAMKK2) Inhibitor Chemotypes

CAMKK2 is a serine/threonine kinase and an activator of AMPK whose dysregulation is linked with multiple diseases. Unfortunately, STO-609, the tool inhibitor commonly used to probe CAMKK2 signaling, has limitations. To identify promising scaffolds as starting points for the development of high-quality CAMKK2 chemical probes, we utilized a hinge-binding scaffold hopping strategy to design new CAMKK2 inhibitors. Starting from the potent but promiscuous disubstituted 7-azaindole GSK650934, a total of 32 compounds, composed of single-ring, 5,6-, and 6,6-fused heteroaromatic cores, were synthesized. The compound set was specifically designed to probe interactions with the kinase hinge-binding residues. Compared to GSK650394 and STO-609, 13 compounds displayed similar or better CAMKK2 inhibitory potency in vitro, while compounds 13g and 45 had improved selectivity for CAMKK2 across the kinome. Our systematic survey of hinge-binding chemotypes identified several potent and selective inhibitors of CAMKK2 to serve as starting points for medicinal chemistry programs.

BENZOFURAN AMIDES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY

The present invention relatesto a pharmaceutical composition comprising acompound of the formula Ias described belowor a tautomeror a pharmaceutically acceptable salt thereof; to the compound of the formula Ias described below or a tautomer or a phar- mac

BENZOFURAN UREAS OR CARBAMATES AND HETEROAROMATIC ANALOGUES THEREOF FOR USE IN THERAPY

The present invention relates to benzofuran ureas or carbamates of formula I and heteroaromatic analogues thereof as described below or a tautomer or a pharmaceutically acceptable salt thereof; to a pharmaceutical composition containing these compounds, and to these compounds for use in therapy, especially for use in the treatment or prevention of a disease or disorder selected from the group consisting of an inflammatory disease, a hyperproliferative disease or disorder, a hypoxia-related pathology and a disease characterized by excessive vascularization. Formula (I) wherein X1 is CR1 or N; X2 is CR2 or N; X3 is CR3 or N; X4 is CR4 or N; with the proviso that at most two of X1, X2, X3 and X4 are N; E1 is O or NR6a; E2 is O or NR6b;with the proviso that E1 and E2 are not simultaneously O; L1 is a bond, optionally substituted C1-C6-alkylene or C3-C8-cycloalkylene; L2 is a bond, optionally substituted C1-C6-alkylene, C3-C8-cycloalkylene, etc.; A is 3-, 4-, 5-, 6-, 7- or 8-membered saturated, partially unsaturated or maximally unsaturated carbocyclic ring or a 3-, 4-, 5-, 6-, 7- or 8- membered saturated, partially unsaturated or maximally unsaturated heterocyclic ring; or L2-A forms a group C1-C6-alkylene-OR13, C1-C6--alkylene-SR14 or C1-C6-alkylene-NR15R16; and R1, R2, R3, R4, R5, R6a, R6b, R13, R14, R15 and R16 are as defined in the claims and the description.

Novel 3beta-amino azabicyclooctane heteroaromatic amid derivatives preparation method and therapeutic uses thereof

The invention concerns compounds of general formula 1, wherein: A, B, D and E represent one or two nitrogen atoms, the others being carbon atoms; X represents a S or, a O, thereby forming a bicyclic fused heteroaromatic, such as thieno[2,3-b]pyridine, furo[2,3-b]pyridine, thieno[3,2-b]pyridine, furo[3,2-b]pyridine, thieno[2,3-b]pyrazine, furo[2,3-b]pyrazine, thieno[2,3-c]pyridine, furo[2,3-c]pyridine, thieno[3,2-c]pyridine and furo[3,2-c]pyridine; R1 represents a linear or branched C1-C6 alkoxy group, a linear or branched C1-C6 alkylthio group; R2 represents a linear, branched, cyclic C2-C8 group, a 2- or 3- thienylmethyl group, or a benzyl group optionally substituted by one or several halogens, F, Cl, Br, I, C1-C4 alkyl, C1-C4 alkoxy, CF3, CN, NO2, OH; and their pharmaceutically acceptable salts. Said compounds are anti-dopaminergic agents.

SPIROFUROPYRIDINE ARYL DERIVATIVES

Compounds of formula (I): and pharmaceutically-acceptable salts thereof, wherein: Ar is a moiety of formula (II) or (III): and A, B, and R1 are as defined in the specification, compositions containing such compounds and the use of such compounds and compositions for use in therapy.

Azabicyclic-substituted fused-heteroaryl compounds for the treatment of disease

The invention provides compounds of Formula I: wherein Azabicyclo is These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful in pharmaceuticals in which α7 is known to be involved.

Quinuclidines-substituted-multi-cyclic-heteroaryls for the treatment of disease

The invention provides compounds of Formula I: 1where in W is 2These compounds may be in the form of pharmaceutical salts or compositions, racemic mixtures, or pure enantiomers thereof. The compounds of Formula I are useful to treat diseases or conditions in which α7 is known to be involved.

Furopyridines. VI. Preparation and Reactions of 2- and 3- Substituted Furopyridines

This paper describes the synthesis and chemical properties of some 2- and 3-substituted furopyridines.Reaction of ethyl 2-chloronicotinate 1 with sodium ethoxycarbonylmethoxide or 1-ethoxycarbonyl-1-ethoxide gave β-keto ester 2 or ketone 5, respectively.Ketonic hydrolysis of 2 afforded ketone 3, from which furopyridine 4 was obtained by the method Sliwa.While, 2-methyl derivative 7 was prepared from 5 by reduction, O-acetylation and the subsequent pyrolysis.Reaction of ketone 3 with methyllithium gave tertiary alcohol 8 which was O-acetylated and pyrolyzed to give 3-methyl derivative 9.Formylation of 4, via lithio intermediate, with DMF yielded 2-formyl derivative 10, from which 7, was obtained by Wolff-Kishner reduction.Dehydration of the oxime 11 of 10 gave 2-cyano derivative 12, which was hydrolyzed to give 2-carboxylic acid 13.Reaction of 3-bromo compound 14 with copper(I)cyanide gave 3-cyano derivative 15.Alkaline hydrolysis of 15 afforded compound 16 and 17, while acidic hydrolysis gave carboxamide 18.Reduction of 15 with DIBAL-H afforded 3-formyl derivative 19.Wolff-Kishner reduction of 19 gave no reduction product 9 but hydrazone 20.Reduction of tosylhydrazone 21 with sodium borohydride in methanol afforded 3-methoxymethylfuropyridine 22.